01 Growing Shift Toward Broader FcRn-Targeted Treatment Recent development is extending these therapies beyond specific antibody-positive groups toward broader patient populations, including patients whose commonly tested antibodies are not detected. This expansion is strengthening myasthenia gravis treatment market trends by increasing the number of patients potentially eligible for targeted therapy and reducing dependence on broad immunosuppression. In May 2026, argenx received U.S. FDA approval expanding VYVGART and VYVGART Hytrulo to all adult generalized myasthenia gravis serotypes, including anti-AChR, anti-MuSK, anti-LRP4, and triple-seronegative patients. The expanded indication made the products the first approved treatments covering all adult gMG serotypes.
02 Increasing Development of More Convenient Self-Administered Treatments Treatment developers are focusing on delivery systems that reduce dependence on hospital-based intravenous administration. Subcutaneous injections and pre-filled devices can give appropriate patients greater flexibility in managing chronic therapy while potentially reducing healthcare-resource requirements. This shift specifically addresses treatment convenience rather than expanding eligible antibody populations. Increasing emphasis on patient-controlled administration is therefore supporting myasthenia gravis treatment market demand for therapies with simpler long-term delivery. In July 2026, UCB presented new data for its zilucoplan pre-filled pen at ICNMD 2026. In a usability study, 90% of adult participants, including injection-naïve patients and caregivers, successfully administered the treatment on their first untrained attempt, while long-term zilucoplan benefits were sustained through Week 120.
01 Growing Treatment Options for Adolescents Expand the Addressable Patient Population Historically, several advanced gMG therapies were initially developed and approved primarily for adults, leaving younger patients with fewer targeted options. Extending modern therapies to adolescents can reduce reliance on older immunosuppressive approaches and provide treatment based more directly on disease mechanisms.
01 Safety Concerns Can Slow Adoption of Highly Intensive Immune Therapies Advanced immune-modifying approaches may potentially deliver deeper disease control but can also introduce safety risks requiring intensive monitoring. This is particularly important for cell therapies that substantially alter immune-cell populations and can trigger serious inflammatory reactions. Safety events can cause clinical holds, extend development timelines, and make regulators and clinicians more cautious about adopting highly intensive treatments. These risks can restrain expansion of the myasthenia gravis treatment market size even when early efficacy signals are promising.
01 B-Cell Depletion Creates a Distinct Targeted Treatment Opportunity B cells play an important role in the autoimmune processes responsible for producing pathogenic antibodies in myasthenia gravis. Therapies targeting specific B-cell populations therefore provide a mechanism distinct from FcRn inhibitors and complement blockers. Expanding therapeutic diversity can help physicians select treatments according to individual disease biology and previous response. Companies establishing differentiated B-cell approaches can strengthen their myasthenia gravis treatment market share while providing additional options for patients with persistent disease.
01 Maintaining Durable Disease Control Without Continuous Treatment Remains Difficult The myasthenia gravis treatment industry continues to face the challenge of achieving sustained symptom control because many targeted therapies suppress specific components of the autoimmune process without permanently eliminating the underlying disease. Developers must balance durable efficacy with infection risk, treatment burden, and long-term immune-system effects when designing therapies for a chronic condition.
June 2026 UCB expanded its immunology and neurology portfolio with additional clinical development activities for rozanolixizumab (Rystiggo®), supporting broader treatment options for patients with generalized myasthenia gravis.
April 2026 Johnson & Johnson expanded its autoimmune disease pipeline through continued development of targeted therapies for neuromuscular disorders, including programs focused on improving treatment outcomes for myasthenia gravis patients.
December 2025 argenx expanded the global availability of VYVGART® Hytrulo, strengthening access to FcRn-targeted therapy for generalized myasthenia gravis through additional market launches and healthcare partnerships.
September 2025 AstraZeneca expanded its rare disease and immunology research portfolio through collaborations focused on developing next-generation biologic therapies for autoimmune disorders, including neuromuscular conditions.